Status:

COMPLETED

Cyclosporine in Patients With Moderate COVID-19

Lead Sponsor:

University of Pennsylvania

Conditions:

COVID-19

Eligibility:

All Genders

18+ years

Phase:

PHASE1

Brief Summary

Phase 1 safety study to determine the tolerability, clinical effects, and changes in laboratory parameters of short course oral or IV cyclosporine (CSA) administration in patients with COVID-19 diseas...

Detailed Description

Our overall hypothesis is that CSA is safe in this patient population and that it will have antiviral and anti-cytokine effects as measured in laboratory tests. The initial dose will be 9 mg/kg/day o...

Eligibility Criteria

Inclusion

  • Provision of signed and dated informed consent form
  • Stated willingness to comply with all study procedures and availability for the duration of the study
  • Male or female, aged \>18.
  • Admitted to hospital with laboratory confirmation of SARS-CoV-2 infection.
  • Estimated creatinine clearance \>50 ml/min using standard Cockcroft-Gault formula.

Exclusion

  • Are admitted to the ICU at time of enrollment.
  • Have an active uncontrolled infection with a non-COVID-19 agent.
  • Have an active malignancy, not including non-melanoma skin cancer, superficial cervical or bladder cancer, MGUS, or prostate cancer with PSA \<1.0.
  • Are on chronic immune suppressive medications, including
  • corticosteroid therapy at a prednisone equivalent dose of 10 mg per day or higher; therapy with calcineurin inhibitors or mTOR inhibitors.
  • Are pregnant
  • Are lactating
  • Have a known allergic reaction to components of the CSA or its diluents.
  • Are receiving investigational vaccine for SARS-CoV-2.

Key Trial Info

Start Date :

June 30 2020

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

October 25 2021

Estimated Enrollment :

11 Patients enrolled

Trial Details

Trial ID

NCT04412785

Start Date

June 30 2020

End Date

October 25 2021

Last Update

January 11 2022

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

University of Pennsylvania

Philadelphia, Pennsylvania, United States, 19104